Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01336842|
Recruitment Status : Completed
First Posted : April 18, 2011
Last Update Posted : January 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumors Non-Small Cell Lung Cancer (NSCLC)||Drug: Panobinostat, Cisplatin, Pemetrexed||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer|
|Study Start Date :||April 2011|
|Primary Completion Date :||January 2017|
|Study Completion Date :||June 2017|
Experimental: Phase I dose-escalation
Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
Drug: Panobinostat, Cisplatin, Pemetrexed
Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.
Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1.
- Safety and feasibility of oral panobinostat in combination with cisplatin and pemetrexed [ Time Frame: Within ±3 days of the scheduled day of assessment except for adverse events that will be evaluated continuously through the study. The expected time frame for this outcome measure is 18 weeks (or six cycles) ]Safety assessments will consist of monitoring and recording all adverse events and serious adverse events, the regular monitoring of hematology, blood chemistry and urine values, regular measurement of vital signs and the performance of physical examination. Safety and tolerability will be assessed according to the NCI CTCAE v4.
- Maximum-tolerated dose as assessed by NCI CTCAE, Version 4.0 [ Time Frame: 3 week cycle; the expected time frame is 18 weeks (or 6 cycles) ]Determination of maximum tolerated dose (MTD) will be based on cycle 1 toxicities
- Dose-limiting toxicities and toxicity profile as assessed by NCI CTCAE, Version 4.0 [ Time Frame: 3 week cycle; the expected time frame is 18 weeks (or 6 cycles) ]Dose-limiting toxicity (DLT) will be based on cycle 1 toxicities.
- Exploratory biomarker analysis [ Time Frame: Blood specimens will be collected prior to treatment, prior to Cycles 2-6. In addition, a blood specimen will be collected if the patient is removed from the study due to progression of disease. the expected time frame is 18 weeks (or 6 cycles) ]Molecular markers predictive for response to panobinostat remain unknown. This trial offers the opportunity to retrospectively study biomarkers and their association with clinical outcomes.
- Efficacy of oral panobinostat in combination with cisplatin/pemetrexed in an expanded cohort of patients with NSCLC [ Time Frame: CT scans will be performed at baseline and every two cycles; the expected time frame is 18 weeks (or 6 cycles) ]Response rate will be assessed by CT scan. CT scans will be performed at baseline and every two cycles. The evaluation of response will be based on standard RECIST criteria.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01336842
|United States, California|
|University of California Davis Cancer Center|
|Sacramento, California, United States, 95817|
|United States, Michigan|
|Henry Ford Health System|
|Detroit, Michigan, United States, 48202|
|Principal Investigator:||David Gandara, MD||University of California, Davis|